Core Insights - TG Therapeutics, Inc. announced the presentation schedule for BRIUMVI (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, focusing on its efficacy in patients with relapsing forms of multiple sclerosis (RMS) [1][2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [24][25] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [4] - The drug is indicated for adults with RMS, which includes various forms of the disease [6] Clinical Trials - The ULTIMATE I & II Phase 3 trials involved 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - Patients in these trials had experienced at least one relapse in the previous year or had specific MRI findings [3] Presentation Details - Presentations at the CMSC meeting include topics on the safety and tolerability of BRIUMVI, with specific focus on infusion reactions and real-world observational data [2][5]